Literature DB >> 9329152

Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.

J T Noga1, T M Hyde, M M Herman, C F Spurney, L B Bigelow, D R Weinberger, J E Kleinman.   

Abstract

INTRODUCTION: Previous postmortem studies of glutamate receptors and uptake sites have shown decreased D-aspartate (D-Asp) (a marker for the high affinity glutamate uptake site) and elevated (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine maleate (MK-801) binding in the putamen in schizophrenia and elevated alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor binding in the caudate nucleus of schizophrenics who committed suicide. The relative effects of schizophrenia, suicide, and neuroleptic treatment in these findings is unclear. This study further explores binding to glutamate receptors (NMDA, kainic acid, and AMPA) and uptake sites in postmortem striatal structures in schizophrenics relative to three control groups (normal controls, neuroleptic-treated controls, and nonpsychotic suicides).
METHODS: We compared the binding densities of tritium-labeled ligands 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), kainic acid (KA), MK-801, and D-Asp, which target the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), KA, and N-methyl-D-aspartic acid (NMDA) ionotropic receptor sites and the glutamate uptake site, respectively, in postmortem striatal/accumbens tissue from six DSM-III-R schizophrenics, eight normal controls, eight neuroleptic-treated controls, and eight suicide victims using standard receptor autoradiographic methods.
RESULTS: Binding of [3H] CNQX (AMPA receptors) was significantly different among the four groups across the subdivisions of the striatum: caudate, putamen, and nucleus accumbens (ANOVA P = .0007, .002, and .004, respectively). The schizophrenia group had higher mean CNQX binding in the caudate nucleus than normal (P = .005) and neuroleptic controls (P = .006) but not suicides (P = .6), who were also higher than normals and neuroleptic-treated controls (P = .05). The binding densities of tritiated MK-801, KA, and D-Asp were not significantly different among the four groups of subjects in any of the striatal regions examined.
CONCLUSIONS: The data suggest there may be an increased density of AMPA receptor sites in the caudate nucleus in schizophrenia that is not apparently due to neuroleptic treatment. A similar increase was also seen the suicide group. Although these data do not confirm previous reports of an increase in [3H]MK-801 or a decrease in [3H]D-Asp binding in the basal ganglia in schizophrenia, the increased caudate AMPA binding observed here could reflect decreased cortical glutamatergic innervation of the caudate. Its implication for suicide is unclear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329152     DOI: 10.1002/(SICI)1098-2396(199711)27:3<168::AID-SYN2>3.0.CO;2-B

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  29 in total

Review 1.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 4.  Pain and suicidality: insights from reward and addiction neuroscience.

Authors:  Igor Elman; David Borsook; Nora D Volkow
Journal:  Prog Neurobiol       Date:  2013-07-01       Impact factor: 11.685

Review 5.  Toward a biosignature for suicide.

Authors:  Maria A Oquendo; Gregory M Sullivan; Katherin Sudol; Enrique Baca-Garcia; Barbara H Stanley; M Elizabeth Sublette; J John Mann
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

6.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

7.  Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression.

Authors:  S Weis; I C Llenos; J R Dulay; N Verma; S Sabunciyan; R H Yolken
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

8.  Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.

Authors:  Sumie Leung; Rodney J Croft; Barry V O'Neill; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

9.  Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.

Authors:  Adolfo Sequeira; Firoza Mamdani; Carl Ernst; Marquis P Vawter; William E Bunney; Veronique Lebel; Sonia Rehal; Tim Klempan; Alain Gratton; Chawki Benkelfat; Guy A Rouleau; Naguib Mechawar; Gustavo Turecki
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

10.  NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.

Authors:  Daniel C Mathews; Erica M Richards; Mark J Niciu; Dawn F Ionescu; Joseph J Rasimas; Carlos A Zarate
Journal:  Transl Neurosci       Date:  2013-06       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.